| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8452900 | Hematology/Oncology and Stem Cell Therapy | 2017 | 8 Pages |
Abstract
VCD afforded better responses than the CTD protocol, and improved patient condition before autologous HSCT. However, more studies are necessary including more patients and addressing various clinical conditions, besides the analysis of cost-effectiveness of these treatments.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Suelen Vigolo, Joice Zuckermann, Rosane Isabel Bittencourt, Lúcia Silla, Diogo André Pilger,